Ashton Thomas Private Wealth LLC Trims Position in United Therapeutics Corporation $UTHR

Ashton Thomas Private Wealth LLC lowered its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 79.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,012 shares of the biotechnology company’s stock after selling 7,913 shares during the quarter. Ashton Thomas Private Wealth LLC’s holdings in United Therapeutics were worth $843,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB lifted its position in United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after acquiring an additional 49 shares during the period. WealthCollab LLC raised its stake in shares of United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares during the last quarter. Rakuten Securities Inc. lifted its holdings in shares of United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 46 shares during the period. True Wealth Design LLC lifted its holdings in shares of United Therapeutics by 738.5% during the third quarter. True Wealth Design LLC now owns 109 shares of the biotechnology company’s stock worth $46,000 after purchasing an additional 96 shares during the period. Finally, Root Financial Partners LLC purchased a new position in United Therapeutics in the 3rd quarter valued at $51,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have commented on UTHR. Royal Bank Of Canada upped their price objective on shares of United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a research report on Thursday, October 30th. UBS Group increased their price target on shares of United Therapeutics from $600.00 to $645.00 and gave the stock a “buy” rating in a report on Tuesday, January 6th. HC Wainwright raised their price objective on shares of United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. Morgan Stanley set a $447.00 target price on United Therapeutics in a research report on Wednesday, October 29th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $575.00 target price on shares of United Therapeutics in a research note on Wednesday, November 19th. Eight equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $509.50.

United Therapeutics Trading Up 1.3%

UTHR stock opened at $485.36 on Friday. The firm has a 50 day moving average of $486.75 and a 200-day moving average of $427.47. The company has a market cap of $20.90 billion, a price-to-earnings ratio of 18.39, a PEG ratio of 2.58 and a beta of 0.85. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $519.99.

Insiders Place Their Bets

In other United Therapeutics news, COO Michael Benkowitz sold 22,500 shares of the business’s stock in a transaction on Monday, November 17th. The stock was sold at an average price of $470.43, for a total transaction of $10,584,675.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Over the last ninety days, insiders sold 542,214 shares of company stock valued at $260,031,533. Company insiders own 10.30% of the company’s stock.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.